baber/WOPTO huggingface dataset:
Patent NZ-584773-A (NZ)
Title: Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
Inventor: LINDQUIST SUSAN L
IPC: A61K31/425
Filed: 2005-09-16
Abstract: Disclosed is the use of a compound of Formula III e.g. 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or a pharmaceutically acceptable derivative thereof as hereinbefore defined, for treating a disease involving a-synuclein toxicity and/or fibril formation, inhibiting or preventing a-synuclein fibril growth, and/or causing disassembly, disruption, and/or disaggregation of n-synuclein fibrils and a-synuclein-associated protein deposits e.g. Parkinson's disease.
Patent NZ-587440-A (NZ)
Title: Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours
Inventor: BENDER STEVEN LEE
IPC: C07K16/28
Filed: 2009-02-04
Abstract: 587440 Provided is an antibody binding integrin alpha 5 beta 1, comprising specified sequences of the six CDRs. Further provided are antibody variants with mutated Fc region, with increased ADCC activity compared to the un-mutated antibody. The antibody can be used to inhibit growth of tumour cells expressing integrin alpha 5 beta 1.
Patent NZ-588752-A (NZ)
Title: Thermomagnetic generator
Inventor: REESINK BENNIE
IPC: H01L37/04
Filed: 2009-04-27
Abstract: Disclosed is a thermomagnetic generator which converts thermal energy to electrical energy without intermediate conversion to mechanical work, and comprises a series of at least three different metal-based thermomagnetic materials whose magnetocaloric effect occurs at different temperatures, such that the conversion of thermal energy to electrical energy can exploit an enlarged temperature range. The compounds suitable for the invention are selected from: (1) (AyBy-1)2+äCwDxEz Where A is Mn or Co, B is Fe, Cr or Ni, C, D and E at least two of C, D and E are different, have a non-vanishing concentration and are selected from P, B, Se, Ge, Ga, Si, Sn, N, As and Sb, where at least one of C, D and E is Ge or Si, (2) La(FexAl1-x)13Hy or La(FexSi1-x)13Hy (II) La(FexAlyCoz)13 or La(FexSiyCoz)13 (III) LaMnxFe2-xGe (IV) 4) Gd5(SixGe1-x)4 (V) (5) Fe2P-based compounds, (6) manganites of the perovskite type, (7) Tb5(Si4-xGex) (VI) or XTiGe (VII) where X = Dy, Ho, Tm, (8) Mn2-xZxSb (VIII) or Mn2ZxSb1-x (IX)
Patent NZ-591490-A (NZ)
Title: Formulations for use in sulfur scale control in industrial water systems
Inventor: RELENYI ATTILA G
IPC: C07C211/03
Filed: 2010-09-30
Abstract: The disclosure relates to a method to control, inhibit and remove elemental sulfur scale in industrial water systems using a formulation containing compound (I) or salts thereof. In compound (I), R is a straight chain or branched chain C6-C24 alkyl or a straight chain or branched chain C6-C24 alkyloxy-C2-C3-alkyl; R1 is a straight chain or branched chain C2-C4alkyl; and X is S, O or N-R2 wherein R2 is H or a straight chain or branched chain C1- C8 alkyl. The composition may also contain water, solvents, diluents, excipients, biocides, stabilizers, surfactants, corrosion inhibitors, scale inhibitors, antifoaming agents and dispersants.
Patent NZ-595346-A (NZ)
Title: Compositions for bowel preparation and methods of use thereof
Inventor: PATTON STEPHANA
IPC: A61K33/42
Filed: 2010-03-26
Abstract: Discloses a method of determining if a subject is a candidate for cleansing of the GI tract with sodium phosphate comprising: determining the phosphate levels in a kidney of the subject wherein normal levels of phosphate in the kidney indicate that the subject is a candidate for cleansing of the GI tract with sodium phosphate.
Patent NZ-596165-A (NZ)
Title: Cellulosic and lignocellulosic structural materials and methods and systems for manufacturing such materials by irradiation
Inventor: MEDOFF MARSHALL
IPC: C12P5/02
Filed: 2009-04-28
Abstract: Disclosed is a method comprising: irradiating a biomass feedstock to change a molecular and/or a supramolecular structure of the biomass feedstock; cooling the irradiated biomass feedstock; and then re-irradiating the biomass feedstock with a second dose of ionizing radiation. Also disclosed is a biomass feed stock produced by the method. The biomass feedstock may be selected from the group consisting of a low molecular weight sugar, a starch, paper, paper products, paper waste, wood, particle board, sawdust, agricultural waste, sewage, silage, grasses, rice hulls, bagasse, cotton, jute, hemp, flax, bamboo, sisal, abaca, straw, corn cobs, corn stover, switchgrass, alfalfa, hay, rice hulls, coconut hair, cotton, synthetic celluloses, seaweed, algae.
Patent NZ-596923-A (NZ)
Title: A Finger Ring with four apertures forming two finger passages
Inventor: HAMPTON MARK ROSS
IPC: A44C9/00
Filed: 2011-12-07
Abstract: A finger ring 1 comprises a body 2, a first finger passage 9 extending between first and second apertures formed in the body 2, and a second finger passage 11 extending between third and fourth apertures formed in the body 2. The first and second apertures are substantially coplanar, and the third and fourth apertures are substantially coplanar.
Patent NZ-598989-A (NZ)
Title: Protective plate for a rotor in a rock crusher
Inventor: HACKWORTH CLINT
IPC: B02C13/14
Filed: 2012-03-23
Abstract: A top wear plate 9 for the rotor of a rock crusher, where the rotor includes a rotor body with an upper surface. The top plate 9 includes a lip positioned about and descending vertically from the underside of the outer circumference of the lip wear plate. The lip includes a protrusion 13 that will engage with a complementary recess on the top surface of the rotor body 1.
Patent NZ-604413-A (NZ)
Title: An electrical connector with insulation displacement contacts
Inventor: PAUL LIN
IPC: H01R4/24
Filed: 2012-12-12
Abstract: An insulation displacement electrical power connector 10 includes a passageway 16 for receiving the cable 26 and cutting edges 28, 30, 32 of respective insulation displacement contacts for cutting into the insulated conductors of the cable to make separate electrical connections thereto when received in the passageway. The cutting edges project up through the floor of the passageway and are aligned longitudinally with the passageway. A movable press 14 is located adjacent to the passageway 16 and is movable between a first position where it allows access of the cable 26 into the passageway and a second position where it presses against the cable 26 and forces it against the cutting edges 28, 30, 32. This causes the cutting edges to cut through the cable 26 and make separate electrical connections to the conductors in the cable substantially simultaneously and longitudinally with reference to the direction of the cable in the passageway.
Patent NZ-608564-A (NZ)
Title: Continuous flow polymerisation process
Inventor: CHIEFARI JOHN
IPC: B01J14/00
Filed: 2011-08-12
Abstract: Disclosed herein is a process for continuously preparing polymer by RAFT (Reversible Action Fragmentation chain Transfer) solution polymerisation, the process comprising: introducing into a flow reactor a reaction solution comprising one or more ethylenically unsaturated monomers, RAFT agent, non- reactive solvent and free radical initiator; and promoting RAFT polymerisation of the one or more ethylenically unsaturated monomers within the reactor so as to form a polymer solution that flows out of the reactor.
Patent NZ-614983-A (NZ)
Title: Tricyclic gyrase inhibitors
Inventor: BENSEN DANIEL
IPC: C07D487/14
Filed: 2012-03-14
Abstract: Disclosed are 2-(aryloxy)-4-(heterocyclyl)-9H-pyrimido[4,5-b]indole derivatives of the general formula (I) or pharmaceutically suitable salts thereof, wherein L is O or S; R8 is H, Cl, Br, OH, amino, alkylamino, aminoalkyl, aminocyclopropyl, methoxy, ethoxy, cyclopropylamino, cyclopropylmethyl, chloromethyl, dichloromethyl, trichloromethyl, CH2CH2Cl, bromomethyl, dibromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, CH2CH2F, CH2CHF2, CH2CF3, NHOH, NHNHCH3, NHOCH3, NHCD3, SCH3 or NHCOH; X, Y and Z are CRX, CRY, and CRZ, respectively, wherein RX is H, methyl, Cl, Br or F; RY is H, methyl, difluoromethyl, trifluoromethyl, cyano, ethyl, Cl, Br, or F; Rz is H, methyl, Cl, Br, or F; R2 is an optionally substituted aryl as defined herein; and R4 is an optionally substituted aryl, optionally substituted aryloxy, substituted amino, or heterocycle connected through a nitrogen atom. Representative compounds include 6-fluoro-4-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-N-methyl-2-[(2-methylpyrimidin-5-yl)oxy]-9H-pyrimido[4,5-b]indol-8-amine. Also disclosed are pharmaceutical compositions comprising a compound as defined above for treating bacterial infections.
Patent NZ-627864-A (NZ)
Title: Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
Inventor: CONG FENG
IPC: C12Q1/68
Filed: 2013-02-22
Abstract: Disclosed is a method of predicting the sensitivity of tumour cell growth to inhibition by a Wnt inhibitor, comprising: a) detecting in a sample of tumour cells from a patient a level of a biomarker, where the biomarker is selected from the group consisting of: (i) DNA copy number at the RNF43 chromosomal region and/or at the ZNRF3 chromosomal region to determine a loss of heterozygosity; (ii) sequenced genomic DNA, cDNA or RNA from cancer tissues to detect an inactivation mutation in the RNF43 gene and/or the ZNRF3 gene; (iii) RNF43 mRNA expression and/or ZNRF3 mRNA expression; (iv) RNF43 protein expression and/or ZNRF3 protein expression; or (v) a combination of biomarkers (i)-(iv): b) comparing the level of the biomarker in the tumour cell sample to a control level of the biomarker selected from the group consisting of: (i) a control level of the biomarker that has been correlated with sensitivity to the Wnt inhibitor; and (ii) a control level of the biomarker that has been correlated with resistance to the Wnt inhibitor; and c) selecting the patient as being predicted to benefit from therapeutic administration of the Wnt inhibitor, if the patient’s tumour has an inactivating RNF43 or ZNRF3 mutation, if the patient’s tumour has a decreased copy number of RNF43 or ZNRF3, or the patient tumour has a decreased expression of RNF43 mRNA or protein or a decreased expression of ZNRF3 mRNA or protein indicates that the patients tumour is likely to be sensitive to Wnt inhibitor.
Patent NZ-628685-A (NZ)
Title: Therapeutic use of p75ntr neurotrophin binding protein
Inventor: WESTBROOK SIMON
IPC: C12N15/00
Filed: 2013-03-14
Abstract: The present invention relates to a p75NTR neurotrophin binding protein, p75NTR(NBP), for use in the treatment of pain and/or a symptom of pain.
Patent NZ-629291-A (NZ)
Title: Anti-robo4-antibody
Inventor: ISUMI YOSHITAKA
IPC: C07K16/46
Filed: 2013-04-26
Abstract: Disclosed is an antibody having properties described in the following (I) to (III) or a functional fragment thereof: (I) binding to the ROB04 protein with a KD value of 1 x 10-8 M or lower; (II) suppressing or inhibiting vascular endothelial cell migration in the absence of a cross-linking antibody in vitro; and (III) suppressing or inhibiting angiogenesis in vivo, wherein the antibody consists of a heavy chain comprising CDRHI consisting of the amino acid sequence represented by SEQ ID NO: 44 (Figure 25), CDRH2 consisting of the amino acid sequence represented by SEQ ID NO: 46 (Figure 26) or an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 46 by the substitution of one amino acid, and CDRH3 consisting of the amino acid sequence represented by SEQ ID NO: 48 (Figure 27) , and a light chain comprising CDRLI consisting of the amino acid sequence represented by SEQ ID NO: 50 (Figure 28) or an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 50 by the substitution of one to three amino acid(s), CDRL2 consisting of the amino acid sequence represented by SEQ ID NO: 52 (Figure 29) , and CDRL3 consisting of the amino acid sequence represented by SEQ ID NO: 54 (Figure 30) (sequences as defined in the specification)
Patent NZ-630763-A (NZ)
Title: Apixaban liquid formulations
Inventor: LUM SUSAN
IPC: A61K47/38
Filed: 2013-09-26
Abstract: Disclosed is an apixaban liquid formulation in which the stability and solubility of apixaban is improved. Also provided is a method of administering an apixaban liquid formulation. The liquid formulation may comprise apixaban, a vehicle which is water, and at least two solubilizers such as non-ionic surfactant, an ionic surfactant, a hydrophilic polymer, ethanol, a polyhydric alcohol, a polyethylene glycol, and a carbohydrate.
Patent NZ-717683-A (NZ)
Title: Crystalline forms of an androgen receptor modulator
Inventor: SMITH NICHOLAS
IPC: C07D401/04
Filed: 2013-06-04
Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
Patent NZ-729346-A (NZ)
Title: Deterministically controlled humidification system
Inventor: BURGESS RUSSEL WILLIAM
IPC: A61M16/16
Filed: 2015-09-03
Abstract: In order to provide a water vaporization system that does not require a reservoir of water, or an excess of water, to be heated, a respiratory humidification system for providing humidification to gases that pass through a gases passage way before being provided to an airway of a patient is proposed and includes: a liquid flow controller for providing a controlled flow of liquid; a heating system including a heating surface configured to be located in a gases passage way and provide humidification to gases passing through the gases passage way, wherein the heating system receives the controlled flow of liquid at the heating surface within the gases passage way to cause at least a portion of the controlled flow of liquid to evaporate within the gases passage way, the heating system configured to maintain the heating surface at a temperature of between 30 °C and 99.9 °C; and one or more hardware processors providing deterministic control of a humidity level of gases passing through the gases passage way by instructing the liquid flow controller to adjust the controlled flow of liquid received at the heating system based on a flow rate of gases through the gases passage way, and an evaporation rate of said controlled flow of liquid from the heating surface.
Patent NZ-729600-A (NZ)
Title: Binding proteins specific for lox1 and uses thereof
Inventor: BUCHANAN ANDREW
IPC: C07K16/28
Filed: 2015-09-30
Abstract: This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.
Patent NZ-731396-A (NZ)
Title: Compositions and methods for the treatment of multiple sclerosis
Inventor: KANDULA MAHESH
IPC: C07C271/16
Filed: 2014-11-20
Abstract: The invention relates to the compounds of formula II or their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of compounds of formula II and methods for treating or preventing multiple sclerosis. The compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous or parenteral administration, as a syrup, or for injection. Such compositions may be used in the treatment of neurodegenerative diseases and other inflammatory diseases.
Patent NZ-736055-A (NZ)
Title: Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
Inventor: SWANSON DEVIN M
IPC: A61P25/00
Filed: 2016-04-28
Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, which can act as inhibitors of AMPA receptors and their use in treating disorders of the central nervous system. Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).
Patent NZ-737774-A (NZ)
Title: Control of timing for mixed-mode multicarrier modulation
Inventor: PARKVALL STEFAN
IPC: H04L27/26
Filed: 2015-11-17
Abstract: Methods and apparatuses for operating a wireless device configured for operation in a wireless communication network are disclosed. In an OFDM-based radio access scheme, narrow and relatively wider subcarriers favor different types of services. The current LTE standard uses fixed subcarrier spacing and, therefore, is relatively inflexible when it comes to satisfying highly varying quality-of-service (QoS) requirements. This is solved by the disclosed techniques and devices which rely on a new physical layer using a smaller and variable sized subframes with its mixed mode operation. In one aspect, a wireless transmitter forms (1110) a first signal having a first integer number of symbol intervals in each of one or more time intervals of a predetermined length and forms (1120) a second signal having a second integer number of symbol intervals in each of the one or more time intervals of the predetermined length, the second integer number differing from the first integer number. The wireless transmitter simultaneously transmits (1130) the first and second signals in a frequency band, such that the first and second signals are frequency-domain multiplexed in the frequency band and such that a symbol interval starting time in the first signal is aligned with a corresponding symbol interval starting time in the second signal at least once per time interval. A wireless receiver adapted to receive and recover the first and second signals is also disclosed. Corresponding techniques for forming and transmitting and/or receiving and recovering the signals are also disclosed as well as apparatus for use in such techniques. Embodiments facilitate operation of wireless devices in a wireless communication network, utilizing the scalability defined for the new physical layer to meet the varying QoS requirements of different applications and services.
Patent NZ-741928-A (NZ)
Title: Laminated wood product
Inventor: FRERES TYLER
IPC: B32B21/14
Filed: 2016-09-22
Abstract: An engineered wood panel assembly to address the limitations on the ability to vary the thickness of wood products manufactured out of laminated timber includes a first layer including a first set of billets that abut against each other along a lengthwise edge of the billets. Each billet includes one or more joints connecting adjacent sheets within the billet, and the joints are oriented perpendicular to the lengthwise edge. Each of the sheets in the first layer includes at least one ply comprising wood grain oriented in a first direction. A second layer including a second set of billets of sheets is layered on top of the first layer. Each billet in the second set includes one or more additional joints that are oriented perpendicular to a lengthwise edge of the second set of billets. The additional joints in the second layer are offset from the joints in the first layer, and each of the sheets in the second layer includes at least one ply having wood grain oriented in a second direction. Additionally, a third layer including a third set of billets of sheets may be layered on top of the second layer.
Patent NZ-745812-A (NZ)
Title: Apparatus for measuring the concentration of target substances in blood
Inventor: CHAUDRY SABIH
IPC: A61B5/145
Filed: 2017-02-15
Abstract: A non-invasive testing apparatus for determining a concentration of a target substance, such as blood sugar, blood alcohol, cholesterol, etc., in a patient’s blood involves applying an output RF signal (102) to the skin of a patient via an antenna (20), and measuring the amplitude and phase of a response signal, which is a function of the output RF signal (102) modified by an interaction with the patient’s blood. Measurements are taken at different output RF frequencies (310), and the response (300) is plotted as a function of frequency (310). Various parameters (552, 554, 556, 550, 408, 410) are derived from the shape of the resulting plots, namely any or more of: a resonance frequency shift; a Q factor of the resonance; a group delay; a phase shift; an amplitude variation; a shape factor of the plot; and a gradient of the plot at different frequencies. Models of the derived parameters as a function of concentration of the target substance in blood are used to arrive at a determination of the latter. Further elements are a circuit (1000) for obtaining the amplitude and phase measurements, a calibration device (5008), a system (3000) for attaching the apparatus to the patient’s body using a pulley belt, and an inflatable bladder system (4000) for ensuring proper sensor contact.
Patent NZ-747549-A (NZ)
Title: Method for preparing azoxystrobin intermediates
Inventor: YANG BINGLIAN
IPC: C07D239/34
Filed: 2018-10-23
Abstract: The present invention provides a method for preparing azoxystrobin intermediates, comprising reacting compound A and dichloropyrimidine in the presence of a trimethylamine catalyst with the addition of a sodium methoxide solution in methanol or the addition of sodium methoxide and methanol separately to produce a mixture of compound B and compound C, with a reaction equation as following. Azoxystrobin intermediate compound B and compound C are synthesized from compound A in the present invention, which is catalyzed by using a trimethylamine catalyst, allowing the reaction to have high efficiency and high yield. In addition, the trimethylamine catalyst has a low boiling point and thus can be easily recycled so that the ammoniacal nitrogen content in wastewater can be reduced, and the difficulties and high costs for wastewater processing can be also reduced. The recycled trimethylamine catalyst can be reused in preparing intermediate compound B, which also has a high catalytic effect and can also achieve a high product yield. The method of the present invention has significant synthetical cost advantages and is suitable for industrial production.
Patent NZ-748129-A (NZ)
Title: Methods of producing epimerases and benzylisoquinoline alkaloids
Inventor: SMOLKE CHRISTINA D
IPC: C12N15/53
Filed: 2016-05-09
Abstract: A method of epimerizing an (S)-1-benzylisoquinoline alkaloid to an (R)-1-benzylisoquinoline alkaloid is provided. The method comprises contacting the (S)-1-benzylisoquinoline alkaloid with at least one epimerase enzyme. Contacting the (S)-1-benzylisoquinoline alkaloid with the at least one enzyme converts the (S)-1-benzylisoquinoline alkaloid to an (R)-1-benzylisoquinoline alkaloid.
Patent NZ-773177-A (NZ)
Title: Neuroactive steroid formulations and methods of treating cns disorders
Inventor: REDDY KIRAN
IPC: A61P25/00
Filed: 2013-01-23
Abstract: Use of allopregnanolone in a cylodextrin carrier in the manufacture of a medicament for treating traumatic brain injury in an individual in need thereof for treatment of a central nervous system injury and for treating a CNS disorder in a subject. Further, a pharmaceutical dosage unit comprising a complex of an alloprenanolone and a cylodextrin.